Perclinical neurochemical and electrophysiological profile of 1192U90, a potential antipsychotic

Neuropsychopharmacology

Volumn 15, Issue 3, 1996, Pages 217-230

  Jones Humble, Stacey A ^a,b   Durcan, Michael J ^a   Lyerly, Donald ^a   Norton, Ronald M ^a   Tang, Flora L M ^a   Russell, Anne V ^a   Watson, Michael J ^a   Gengo, Peter J ^a   Morgan, Philip F ^a   Wang, Ching M ^a   Cooper, Barrett R ^a   Richard F C , Cox ^a  

^a Burroughs Wellcome Co   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Atypical antipsychotic; Dopamine; Dopamine turnover; Dorsal raphe nucleus; HPLC; Neurotransmitter; Receptor; Serotonin; Single unit recording; Substantia nigra; Uptake; Ventral tegmental area

Indexed keywords

2 AMINO N [4 [4 (1,2 BENZISOTHIAZOL 3 YL) 1 PIPERAZINYL]BUTYL]BENZAMIDE; APOMORPHINE; CLOZAPINE; DEXAMPHETAMINE; DOPAMINE; NEUROLEPTIC AGENT; NORADRENALIN; PROPRANOLOL; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; AMPHETAMINE; BIOGENIC AMINE; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BRAIN LEVEL; ELECTROPHYSIOLOGY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; BRAIN; DRUG EFFECT; MALE; METABOLISM; NERVE CELL; PHYSIOLOGY; RADIOASSAY;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BIOGENIC AMINES; BRAIN; CLOZAPINE; MALE; NEURONS; PIPERAZINES; RADIOLIGAND ASSAY; RATS; THIAZOLES;

EID: 0030222489     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(96)00019-X     Document Type: Article

References (92)

1. Aghajanian GK, Bunney BS (1977): Dopamine "autoreceptors": Pharmacological characterization by microiontophorectic single cell recording studies. Naunyn Schmiedebergs Arch Pharmacol 297:1-7
2. 1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 64:3-5
3. Andersson JL, Marcus M, Nomikos GG, Svensson TH (1994): Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn Schmiedbergs Arch Pharmacol 349:236-243
4. Andreasen, NC (1988): Brain imaging: Applications in psychiatry. Science 239:1381-1388
5. 3H]-substance P to the rat submaxillary gland. J Pharmacol Exp Ther 234:326-336
6. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992): Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 17(suppl):12-16
7. 1 receptor antagonist ligand, in rat s triatum. Life Sci 35:1885-1893
8. Bunney BS (1992): Clozapine: A hypothesized mechanism for its unique clinical profile. Br J Psychiatry 17:(suppl) 17-21
9. Bunney BS, Aghajanian GK (1978): d-Amphetamine-induced depression of central dopamine neurons: Evidence for mediation by both autoreceptors and a striatonigral feedback pathway. Naunyn-Schmiedebergs Arch Pharmacol 304:255-261
10. Bunney BS, Grace AA (1978): Acute and chronic haloperidol treatment: Comparison of effect on nigral dopaminergic activity. Life Sci 23:1715-1728
11. Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973): Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571
12. Burcher E, Buck SH, Lovenberg W (1986): Characterization and autoradiographic localization of multiple tachykinin binding sites in gastrointestinal tract and bladder. J Pharmacol Exp Ther 236:819-831
13. Bürki HR, Ruch W, Asper H (1975): Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the bigenic amines in the brain of the rat. Psychopharmacologia (Berl.) 41:27-33
14. Bürki HR, Ruch W, Asper H, Baggiolini M, Stille G (1974): Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat. Eur J Pharmacol 27:180-190
15. Carlsson A, Lindqvist M (1963): Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144
16. Casey DE (1989): Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacol 99(suppl):S47-S53
17. 4. Biochem Biophys Res Commun 118:20-26
18. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
19. Chiodo LA, Bunney BS (1983): Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3:1607-1619
20. Chiodo LA, Bunney BS (1985): Possible mechanisms by which repeated clozapine administration differentially affects the activity of two populations of midbrain dopamine neurons. J Neurosci 5:2539-2544
21. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tauson B, Klerman G (1987): The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7:377-384
22. 2 receptors: Implications for drug mechanisms of action. Life Sci 39:2571-2580
23. Coward DM (1992): General pharmacology of clozapine. Br J Psychiatry 17(suppl):5-11
24. Cox RF, Neumeyer JL, Waszczak BL (1988): Effects of N-n-propylnorapomorphine enantiomers on single unit activity of substantia nigra pars compacta and ventral tegmental area dopamine neurons. J Pharmacol Exp Ther 247:355-362
25. 1A agonists. Synapse 14:297-304
26. D'Ambra TE, Estep KG, Bell MR, Eissenstat MA, Josef KA, Ward SJ, Haycock DA, Baizman ER, Casiano FM, Beglin NC, Chippari SM, Grego JD, Kullnig RK, Daley GT (1992): Conformationally restrained analogues of Pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 35: 124-135
27. 3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity. J Pharmacol Exp Ther 250:696-706
28. 4 receptor? Life Sci 57:PL275-283
29. Eshleman AJ, Murray TF (1990): Dependence on gammaaminobutyric acid of pyrethroid and 4′-chlorodiazepam modulations of the binding of t-[35S]-butylbicyclophosphorothionate in piscine brain. Neuropharmacology 29:641-648
30. 3H]-dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther 210:244-428
31. Gallagher DW, Aghajanian GK (1976): Effect of antipsychotic drugs on the firing of dorsal raphe cells. I. Role of adrenergic system. Eur J Pharmacol 39:341-355
32. Gerlach J, Koppelhus P, Helweg E, Monrad A (1974): Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410-424
33. Goedert M, Pittaway K, Williams BJ, Emson PC (1984): Specific binding of tritiated neurotensin to rat brain membranes: Characterization and regional distribution. Brain Res 304:71-81
34. 3H-glyburide, to neuronal and muscle preparations. J Pharmacol Exp Ther 257:1162-1171
35. 3H]-Nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists. Proc Nat Acad Sci USA 79:3656-3660
36. 3H-PAT. Nature 305:140-142
37. Greenberg DA, U'Prichard DC, Snyder SH (1976): Alphanoradrenergic receptor binding in mammalian brain: Differential labeling of agonist and antagonist states. Life Sci 19:69-76
38. Grenhoff J, Svensson TH (1994): Prazosin modulates the firing pattern of dopamine neurons in the rat ventral tegmental area. Eur J Pharmacol 233:79-84
39. Griffith RW, Saameli K (1975): Clozapine and agranulocytosis. Lancet 2(7936):657
40. 4 receptors in guinea-pig and rat brain. Brit J Pharmacol 109:618-624
41. Hacksell U, Jackson DM, Mohell N (1995): Dose the dopamine receptor subtype selectivity of antipsychotic agents provide useful leads for the development of novel therapeutic agents? Pharmacol Toxicol 76:320-324
42. Hicks PB (1990): The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47:1609-1615
43. Hwang S, Lam M, Pong S (1986): Ionic and GTP regulation of binding of platelet-activating factor to receptors and platelet-activating factor-induced activation of GTPase in rabbit platelet membranes. J Biol Chem 261:532-537
44. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva I (1975): Clozapine and agranulocytosis. Lancet 2(7935):611
45. Imperato A, Aupclucci L (1988): The effects of clozapine and fluperlapine on the in vivo release and metabolism of dopamine in the striatum and in the prefrontal cortex of freely moving rats. Psychopharmacology Bulletin 25:383-389
46. Jackson DM, Ryan C, Evenden J, Mohell N (1994): Preclinical findings with new antipsychotic agents: What makes them atypical? Acta Psychiatr Scand 89(suppl 380):41-48
47. 2-receptors in prefrontal cortex and hippocampus. J Neurochem 53:1772-1781
48. Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
49. 2 receptor selectivity of dopamine receptor antagonists: Possible therapeutic implications. Eur J Pharmacol 236:483-486
50. Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz BL, Howard A (1988): Clozapine-induced agranulocytosis: Non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 49:271-277
51. Lieberman JA (1993): Understanding the mechanism of action of atypical antipsychotic drugs. Br J Psychiatry 22:(suppl)7-18
52. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21:301-314
53. 3 receptor agonist 7-OHDPAT: Lack of mesolimbic selectivity. Eur J Pharmacol 264:269-278
54. Lowe JA III, Seeger TF, Nagel AA, Howard HR, Seymour PA, Heym JH, Ewing FE, Newman ME, Schmidt AW, Furman JS, Vincent LA, Maloney PR, Robinson GL, Reynolds LS, Vinick FJ (1991): 1-Naphthylpiperaszine derivatives as potential atypical antipsychotic agents. J Med Chem 34:1860-1866
55. 2+ mobilization, and phosphorylase activation in rat liver. Mol Pharmacol 28:93-99
56. 3 receptors. Mol Pharmacol 43:749-754
57. 3H]Dipyridamole binding to guinea pig brain membranes: Possible heterogeneity of central adenosine uptake sites. J Neurochem 48:1231-1236
58. Marangos PJ, Martino AM (1981): Studies on the relationship of gamma-aminobutyric acicl-stimulated diazepam binding and the gamma-aminobutyric acid receptor. Mol Pharmacol 20:16-21
59. McMillen BA, Scott SM, Davanzo EA (1988): Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J Pharm Pharmacol 40:885-887
60. Meltzer, HY (1991): The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:265-287
61. Meltzer HY (1992): The importance of serotonin-dopamine interactions in the actions of clozapine. Br J Psychiatry 17:(suppl)22-29
62. Meltzer HY, Bastani B, Young Kwon K, Ramierz LF, Sharpe J (1989): A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacol 99: S68-S72
63. Mereu G, Lilliu V, Vargiu P, Muntoni LS, Diana M (1995): Depolarization inactivation of dopamine neurons: An artefact? J Neurosci 15:1144-1149
64. 2 adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol 16:34-36
65. 3 receptor in rat brain. Peptides 11:827-836
66. 3 binding sites in rat brain cortical membranes. Biochem Pharmacol 38:1693-1695
67. 1C binding sites in rat frontal cortex. J Neurochem 47:529-540
68. 2+ release channel. Circ Res 67:84-96
69. 3H]Desmethoxyverapamil labels multiple calcium channel modulator receptors in brain and skeletal muscle membranes: Differentiation by temperature and dihydropyridines. J Pharmacol Exp Therap 237:731-738
70. Rigdon GC, Norman MH, Cooper BR, Howard JL, Boncek VM, Faison WL, Nancy KP, Pollard GT (1996): 1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects. Neuropsychopharmacology 15:231-242
71. Rogawaski MA, Aghajanian GK (1981): Serotonin autoreceptors on dorsal raphe neurons: Structure-activity relationships of tryptamine analogs. J Neurosd 1:1148-1154
72. 2-adrenoceptors. Naunyn-Schmiedebergs Arch Pharmacol 321:253-259
73. Saito A, Goldfine ID, Williams JA (1981): Characterization of receptors for cholecystolinin and related peptides in mouse cerebral cortex. J Neurochem 37:483-490
74. Schotte A, Janssen PF, Megens AA, Leysen JE (1993): Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantiative autoradiography. Brain Res 631:191-202
75. 4. Neuropsychopharmacology 7:261-284
76. Shopsin B, Klein H, Aaronsom M, Collora M (1979): Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: A controlled, doubleblind comparison. Arch General Psychiatry 36:657-664
77. 1B-adrenoceptors. Eur J Pharmacol 238:407-410
78. Slotkin TA, Cowdery TS, Orband L, Pachman S, Whitmore WL (1986): Effects of neonatal hypoxia on brain development in the rat: Immediate and long-term biochemical alterations in discrete regions. Brain Res 374:63-74
79. 1A selective agonists. Eur J Pharmacol 128:295-298
80. 1B agonists. Synapse 1:3-9
81. 2 receptors. J Pharmacol Exp Ther 266:1374-1384
82. Sunahara RK, Seeman P, Van Tol HHM, Niznik HB (1993): Dopamine receptors and antipsychotic drug response. Br J Psychiatry 22(suppl):31-38
83. Tam SW (1983): Naloxone-inaccessible sigma receptor in rat central nervous system. Proc Nat Acad Sci U S A 80: 6703-6707
84. Tarsy D (1983): Neuroleptic-induced extrapyramidal reactions: Classification, description and diagnosis. Clin Neuropharmacol 6(suppl 1):S9-S26
85. 1A receptor-related anxiolytics. Trends Pharmacol Sci 8:432-437
86. VanderMaelen CP, Aghajanian GK (1983): Electrophysiological and pharmacological characterization of sertonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res 289:109-119
87. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614
88. 2 muscarinic receptor subtypes. Life Sci 32:3001-3011
89. 1 binding data. Life Sci 51: 1869-1876
90. White FJ, Wang RY (1983a): Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci 32:983-993
91. White FJ, Wang RY (1983b): Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054-1057
92. White FJ, Wang RY (1984): Pharmacological characterization of dopamine autoreceptors in the rat ventral tegmental area: Microiontophoretic studies. J Pharmacol Exp Ther 231:275-280